Corbus Pharmaceuticals (CRBP) News Today

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has mixed analyst signals: firms continue to see substantial potential, but recent earnings revisions point to ongoing losses and the stock has weakened considerably from its 52-week high.

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target. It raised its estimated earnings per share for 2027 and 2028 by narrowing projected losses, which supports its longer-term optimism. Corbus analyst estimates
• Positive Sentiment: Mizuho kept its Outperform rating and lowered its price target only modestly, from $24 to $23. The target remains far above the recent share price, though it is still an analyst forecast rather than a near-term catalyst. Corbus price target lowered at Mizuho
• Negative Sentiment: HC Wainwright lowered its Q4 2026 and full-year 2026 EPS forecasts, and reduced estimates for 2029 and 2030. Its revised 2030 estimate now projects a small loss instead of a profit, underscoring uncertainty about the path to profitability. Corbus analyst estimates
• Negative Sentiment: Recent financial results add pressure: Corbus reported a quarterly loss per share wider than analysts expected. Shares have also fallen substantially from their 52-week high, leaving investors focused on execution and future progress. Analyst insights on Corbus and other healthcare companies